Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors

Next Previous
X
Search
Trial Profile

A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Ribociclib (Primary) ; Ribociclib (Primary) ; Dexamethasone
  • Indications Anaplastic astrocytoma; Brain cancer; CNS cancer; Diffuse intrinsic pontine glioma; Ependymoma; Germ cell and embryonal neoplasms; Glioblastoma; Glioma; Medulloblastoma
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 05 Feb 2021 Results (n=22) assessing safety and pharmacokinetic properties of ribociclib and everolimus in children with recurrent or refractory malignant brain tumors published in the Clinical Cancer Research.
    • 26 May 2020 Planned End Date changed from 31 Jul 2020 to 1 Apr 2020.
    • 26 May 2020 Planned primary completion date changed from 31 Jul 2020 to 1 Apr 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top